Navigation Links
Chemotherapy Induced Nausea and Vomiting (CINV) Existing and Pipeline Drugs Market is Expected to Reach USD 2.1 Billion Globally in 2018: Transparency Market Research
Date:11/28/2012

ALBANY, New York, November 28, 2012 /PRNewswire/ --

According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron FDC, APF530 & Rolapitant) Market - Global Market Opportunity Assessment Study, 2012 - 2018," the global CINV market was worth USD 1.3 billion in 2011 and is expected to reach USD 2.1 billion in 2018, growing at a CAGR of 7.1% from 2013 to 2018. The North American CINV existing and pipeline drugs market is expected to reach USD 1.0 billion in 2018. Sluggish economic growth and a poor reimbursement scenario in European countries have hampered the growth of CINV drugs market in these regions.

.

Browse the full report at http://www.transparencymarketresearch.com/cinv-market.html

Nausea and vomiting represent the most frequent side-effects experienced by chemotherapy patients, referred to as chemotherapy-induced nausea and vomiting (CINV), which is debilitating to cancer patients. Emetogenic refers to the likelihood of a chemotherapy drug affecting the patient in an adverse manner, leading to added illness or sickness. Highly emetogenic chemotherapy (HEC) mostly leads to nausea and vomiting in 90% or more of the cases, while moderately emetogenic chemotherapy (MEC) causes nausea and vomiting in 30-90% of the cases.

Current drug treatments available to prevent CINV have failed to completely overcome the symptoms of this disease. Moreover, most of the drugs are approved for acute-onset CINV whereas there is no drug approved yet for delayed-onset CINV for patients receiving HEC, which occurs more frequently (50-70% of patients) in the cancer population. The inefficiency to effective
'/>"/>

SOURCE Transparency Market Research
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
2. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
3. Gold nanoparticles could treat prostate cancer with fewer side effects than chemotherapy
4. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
5. First-of-its-kind self-assembled nanoparticle for targeted and triggered thermo-chemotherapy
6. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
7. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
8. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
9. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
10. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
11. Arteriocyte Takes the Lead in Promoting Building Future Pipeline of Women in STEM Career Fields
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and BANGALORE, India , July ... profiling company that uses next generation sequencing technology to ... Scott A. Storrer as chief executive officer. In ... will be responsible for all strategy, business expansion and ... who has served as Strand,s chairman and CEO since ...
(Date:7/1/2015)... July 1, 2015 InferMed ... will ... evidence-based clinical s olutions suite   ... medical information products and services, announced today the acquisition of  ... support (CDS) technology company. InferMed,s Arezzo technology supports ...
(Date:6/30/2015)... ... , ... Students and faculty from Beijing City University will ... Biotechnology,” an applied biotechnology course team-taught by faculty members from both institutions. The ... both universities and is taught on both continents. , “Our alliance with Beijing ...
(Date:6/30/2015)... June 30, 2015  Today, Americord Registry, one of the ... Andrew Horne , a partner at Kirkland & Ellis LLP, ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are ... Board," says Martin Smithmyer , CEO of Americord. "He ... career that will assist Americord,s growth and vision." ...
Breaking Biology Technology:Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... 2011 Cross reference:   Picture ... be downloaded free of charge at:   http://www.presseportal.de/pm/18701/eppendorf-ag?keygroup=bild ... Science from 2008, Dr. Andrew Holt and ... how chemicals used as manufacturing additives can substantially inhibit ...
... HANOVER, N.J., Dec. 2, 2011 Novartis Pharmaceuticals Corporation ... presentations on data from its robust oncology portfolio at ... for patients with cancers and hematological diseases. ... held from December 6-10, will feature data presentations from ...
... Ltd. - (OTCBB: HADSY), a publicly traded portfolio of ... owned by the Hadassah University Hospital, Israel,s foremost medical ... companies have received grant approvals from the Israeli Office ... Industry, Trade and Labor. These approvals ...
Cached Biology Technology:Eppendorf Video Features Dr Andrew Holt's Work on Bioactive Leachates From Plastic Consumables 2Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 2Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 3Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 4Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 5Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 6Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 7Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 8Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 9Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 10Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 11Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 12Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 13Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 14Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 15Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 16Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 17Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 18Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 19Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 20Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts 21Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies 2
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... researchers and collaborators have found, in a previously identified ... five cases of isolated cleft lip. It is the ... cleft lip alone, rather than both cleft lip and ... unknown genetic mechanism and could eventually help with diagnosis, ...
... Journal of Cell Biology how the altered behavior ... On 2D surfaces, cells may migrate randomly, or be ... extracellular matrix, are known to influence the mode of ... has suggested that an integrin called a5b1 drives random ...
... New material could speed development of hydrogen powered vehicles ... design of a new material that almost meets the U.S. ... could help eliminate a key roadblock to practical hydrogen-powered vehicles. ... explosive gas, is scheduled for the Oct. 8 issue of ...
Cached Biology News:Study finds genetic variant plays role in cleft lip 2Study finds genetic variant plays role in cleft lip 3American Chemical Society's Weekly PressPac 2American Chemical Society's Weekly PressPac 3American Chemical Society's Weekly PressPac 4American Chemical Society's Weekly PressPac 5American Chemical Society's Weekly PressPac 6American Chemical Society's Weekly PressPac 7American Chemical Society's Weekly PressPac 8
... SYBR Green I nucleic acid gel stain ... that has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... acid stain has also found uses in capillary ...
Synonym: modified Grace's Insect medium...
... The active ingredient in Molecular ... which appears to act as a ... fluorescence emission. Our original SlowFade formulation ... fading rate of fluorescein to almost ...
... is a proteohormone with a molecular weight of 16 ... ob gene and produced by adipocytes [1,2]. Leptin ... regulation of body weight [1-3]. In the human, ... men and women [4]. A relationship between serum ...
Biology Products: